Haemodynamic optimisation improves tissue microvascular flow and oxygenation after major surgery: a randomised controlled trial.
BACKGROUND
Post-operative outcomes may be improved by the use of flow related end-points for intra-venous fluid and/or low dose inotropic therapy. The mechanisms underlying this benefit remain uncertain. The objective of this study was to assess the effects of stroke volume guided intra-venous fluid and low dose dopexamine on tissue microvascular flow and oxygenation and inflammatory markers in patients undergoing major gastrointestinal surgery.


METHODS
Randomised, controlled, single blind study of patients admitted to a university hospital critical care unit following major gastrointestinal surgery. For eight hours after surgery, intra-venous fluid therapy was guided by measurements of central venous pressure (CVP group), or stroke volume (SV group). In a third group stroke volume guided fluid therapy was combined with dopexamine (0.5 mcg/kg/min) (SV & DPX group).


RESULTS
135 patients were recruited (n = 45 per group). In the SV & DPX group, increased global oxygen delivery was associated with improved sublingual (P < 0.05) and cutaneous microvascular flow (P < 0.005) (sublingual microscopy and laser Doppler flowmetry). Microvascular flow remained constant in the SV group but deteriorated in the CVP group (P < 0.05). Cutaneous tissue oxygen partial pressure (PtO2) (Clark electrode) improved only in the SV & DPX group (P < 0.001). There were no differences in serum inflammatory markers. There were no differences in overall complication rates between the groups although acute kidney injury was more frequent in the CVP group (CVP group ten patients (22%); pooled SV and SV & DPX groups seven patients (8%); P = 0.03) (post hoc analysis).


CONCLUSIONS
Stroke volume guided fluid and low dose inotropic therapy was associated with improved global oxygen delivery, microvascular flow and tissue oxygenation but no differences in the inflammatory response to surgery. These observations may explain improved clinical outcomes associated with this treatment in previous trials.


BACKGROUND
ISRCTN 94850719.
Jhanji
Shaman
S
Barts and The London School of Medicine and Dentistry, Queen Mary's University of London, Turner Street, London E1 2AD, UK. shaman.jhanji@bartsandthelondon.nhs.uk
Vivian-Smith
Amanda
A
Lucena-Amaro
Susana
S
Watson
David
D
Hinds
Charles J
CJ
Pearse
Rupert M
RM
D000368:Aged; D001784:Blood Gas Analysis; D002496:Central Venous Pressure / Q000502:physiology; D013505:Digestive System Surgical Procedures / Q000379:methods*; D004298:Dopamine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D005440:Fluid Therapy / Q000379:methods; D006439:Hemodynamics / Q000502:physiology; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood; D053583:Interleukin-1beta / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D007430:Intraoperative Care / Q000379:methods*; D008297:Male; D008833:Microcirculation / Q000502:physiology*; D008875:Middle Aged; D010100:Oxygen / Q000097:blood*; D010313:Partial Pressure; D016037:Single-Blind Method; D013318:Stroke Volume; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D014665:Vasodilator Agents / Q000627:therapeutic use
D053583:Interleukin-1beta; D015850:Interleukin-6; D016209:Interleukin-8; D014409:Tumor Necrosis Factor-alpha; D014665:Vasodilator Agents; D018799:Intercellular Adhesion Molecule-1; C046318:dopexamine; D010100:Oxygen; D004298:Dopamine